PRAC reviews European Medicines Agency (EMA) guidance on risk management plan requirements for COVID-19 vaccines

EMA’s safety committee (PRAC) has reviewed guidance developed by EMA for pharmaceutical companies on how to prepare risk management plans for COVID-19 vaccines. Guidance will now be sent for adoption to EMA’s human medicines committee (CHMP) and made public once adopted.

Source:

European Medicines Agency